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Abstract
Background: It has been proven that the interaction between pharmaceutical representatives and physicians
can directly influence the latter’s prescribing behaviour. This meta-synthesis aims to explore the available studies
regarding the nature of the interaction that takes place between pharmaceutical representatives and physicians.
It highlights the different aspects of that interaction by investigating the reasons why these meetings happen
in the first place, their benefits and drawbacks and their impact on patients’ health and, ultimately, the health of
the public.
Methods: A search for published articles was conducted in April 2015. Three databases (PubMed, Ovid Medline,
and ProQuest) were searched for articles published between January 2000 and April 2015. Authors worked
autonomously and in pairs to select eligible articles. In this case, the meta-synthesis approach was used to develop
a fuller understanding and to facilitate new knowledge by bringing together qualitative findings on physician-PR
interaction. ‘Meta-synthesis’ is the process of amalgamation of a group of similar studies with the aim of developing
an explanation for their findings (Walsh and Downe, J Advanc Nurs 50: 204–211, 2005). A thematic content analysis
was conducted on the 15 included full text articles (qualitative and quantitative studies) whereby the original
authors’ understanding of key concepts in each study was identified and listed in a summary form in the data
extraction sheet under “key findings” column. These findings were then juxtaposed to identify homogeneity
and dissonance (Walsh and Downe, J Advanc Nurs 50: 204–211, 2005). Homogenous findings were then coded
together on a different data extraction table to form a theme.
Results: A total of 15 articles met the inclusion criteria and were included in this meta-synthesis;six from the United
States, two from Libya, and one each from Turkey, Peru, India, Germany, the United Kingdom, Yemen, and Japan.
Six main themes were derived from the included articles: 1-the frequency of pharmaceutical representatives’ visits,
2-the perceived ethical acceptability of the interactions between pharmaceutical representatives and physicians,
3-the attitudes held by physicians towards visits by pharmaceutical representatives, 4-their perception of the effect
of such visits on prescription patterns, 5-reasons to accept or reject pharmaceutical representatives, and lastly,
6-guidelines.
Conclusions: The physicians referred to pharmaceutical representatives as efficient and convenient information
resources and were willing to meet them and accept their gifts. It was also evident that most physicians believed
that their prescribing would not be influenced by pharmaceutical representatives.
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Background
The pharmaceutical industry significantly influences the
economy and healthcare system of a country. According
to The World Health Organization(WHO), by 2017,the
global pharmaceuticals market will be worth approxi-
mately US$400billion with one third of thesales revenue
of pharmaceutical companies spent on marketing their
products [1]. Physicians are the prime target of pharma-
ceutical marketing teams, in which pharmaceutical
representatives (PRs) play a crucial role [1]. The job of
the PRs is to visit physicians to promote their company’s
products [2, 3]. In addition, free physician samples, gifts,
company supported conferences, workshops and events
are also brought to the notice of physicians through PRs.
Among all the promotional expenses, detailing is the lar-
gest category; estimated US$20.4 billion has been used
for this purpose in United States (US) in 2015 [4, 5].
Given the above, PR-physician interactions have the
potential to result in a conflict of interest whereby
physicians might fail to abide by their moral, legal and
professional obligations for personal gain [6, 7]. Research
has shown that the interaction between PRs and the
physicians can directly influence the latter’s prescribing
behaviour; it has been observed that the rate of prescrip-
tions increases after physicians see a PR or accept free
samples [8]. This has led to increasing concern over ir-
rational and inappropriate prescribing practices [9]
which could jeopardize patient care, harm the patients,
promote the misuse of drugs, increase costs to the
healthcare system, distort public opinion of the health-
care industry and erode the trust of the patients in the
integrity of medical decision making [8, 10].
Wazana et al., published a review in 2000 that identi-
fied the extent of and attitudes toward the interplay of
relationship and its impact between physicians towards
the PR [11]. Wazana’s review received a mixed response
from the health care communities because he proposed
that the extent of physician-PR interactions could
potentially affect prescribing and professional behaviour
[12–18]. Ten years later, Spurling et al. who performed a
systematic review on 58 articles, reported that exposure
to information from pharmaceutical companies was as-
sociated with either lower prescribing quality or increase
in prescribing frequency or no association was detected.
Finally, with only one exception among the 58 studies
included in the review by Spurling et al.; exposure to
information from PRs was associated with an increase in
prescribing costs or no association was detected. They
reported that interaction of physicians with PRs does
not negatively affect prescribing [3]. This is the first
meta-synthesis that fills the literature gap on the inter-
action between PRs and physician. The purpose of this
meta-synthesis, therefore, is to explore the available
studies regarding PR-physician interactions especially to
highlight the detailing aspects of such interactions from
the physician’s point of view.
Methods
A systematic literature search of computerized databases
was conducted in April 2015 using PubMed, Ovid Med-
line and ProQuest. A meta-synthesis approach was used
to integrate results from various studies in order to give
a comprehensive overview of the interaction that takes
place between pharmaceutical representatives and phy-
sicians [19]. Research papers published between January
2000 and April 2015 which presented evidence con-
cerning such interactions, were included. The search
strings used can be found in Supporting Information
Additional file 1: Table S1.
The search strings used were very specific. This is be-
cause we were not interested in marketing methods
other than detailing. Our purpose was to focus on the
interaction that takes place between PRs (and not any
other promoter/ representatives from other industries
who might meet with physicians) and physicians (and
not any other prescriber such as prescribing nurses,
dentists, etc.). Hence the search strings were chosen
carefully to retrieve the most relevant studies. To ensure
all relevant papers were included, we searched the refer-
ences of the studies that were included. Furthermore,
Monash integrated search panel for Science Citation
Index were also used to screen the relevant citations of
the included studies.
A total of 218 papers were identified using the search
strings outlined in Additional file 1: Table S1. Duplicates
and articles published before the year 2000 were ex-
cluded. The title and abstract of the 72 remaining papers
were assessed for eligibility against the inclusion criteria.
This was performed independently by two reviewers,
who classified the papers into three groups of “to in-
clude”, “to exclude” and “unclear”. Both reviewers (SS
and TMK) met to compare their independent reviews. A
paper would be included or excluded once agreed by
both reviewers. In the case of disagreement, or when
either reviewer was unsure, the opinion of a third person
(LCM) was sought.
The inclusion criteria were articles focusing on detail-
ing and physician interaction with PRs. Studies related
to marketing methods other than detailing, such as
direct to consumer advertising and ghost writing were
excluded. Papers written in languages other than English
were excluded as we did not have the necessary skills to
interpret them. We also excluded studies focused on
prescribers other than physicians, such as prescribing
nurses. Opinion papers and interventional studies were
also excluded.
The full text of 25 papers was read by the first author.
A number of studies were identified at this stage as not
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being written in English (i.e. their title and abstract were
written in English but the full-text was not) and these
were therefore excluded, along with a number of others
that were found to be irrelevant. This left 15 papers.
Details about the number of the included and excluded ar-
ticles are shown in Fig. 1. The Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
checklist is presented in Additional file 2: Table S2.
Analysis and theme synthesis
‘Qualitative meta-synthesis’ is the process of amalgam-
ation of a group of similar qualitative studies with the
aim of developing an explanation for their findings [20].
In this case, the meta-synthesis approach was used to
develop a fuller understanding and to facilitate new
knowledge by bringing together qualitative findings on
physician-PR interaction. The 15 included papers were
subjected to data extraction using a pre-designed data-
extraction Excel worksheet on Microsoft Office® 2014. A
thematic content analysis was conducted on the15
included full text articles whereby the original authors’
understanding of key concepts in each study was identi-
fied and listed in a summary form in the data extraction
sheet under “key findings” column. These findings were
then juxtaposed to identify homogeneity and dissonance
[20]. Homogenous findings were then coded together on
a different data extraction table to form a theme. Six
broad themes were formulated for the results section; 1-
The frequency of pharmaceutical representatives’ visits, 2-
The perceived ethical acceptability of the PR-physician
interactions, 3-Physicians’ attitudes towards PR visits, 4-
Physicians’perceptions of the effect of PR visits on
prescription patterns, 5-Reasons to accept/reject PRs and
6-Guidelines. Findings were scrutinized under each theme
to see if further sub-categories were warranted. The argu-
ments for and against PR interaction with physicians were
very rich. We were hence unable to take account of all the
arguments, in great detail. Moreover, while all the in-
cluded studies presented information about PR-physician
interactions, they reported different aspects of such inter-
actions since they examined the interaction from different
angles, hence a thematic analysis was chosen to classify
and summarize the findings in a systematic, easy to under-
stand manner. Through the six themes formulated, we
hope to provide an overview of the main aspects of the
PR-physician interactions identified.
Fig. 1 PRISMA diagram demonstrating the search strategy and its results
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Results
A total of 15 publications were included in the study
covering studies undertaken in a range of countries; six
from the US, two from Libya, one each from Turkey,
Peru, India, Germany, the United Kingdom (UK), Yemen
and Japan. Eight of these articles focused on physicians’
attitudes and views regarding physician-PR interactions
[9, 21–27]; four focused on the nature of the interaction
[26, 28–30]; two concentrated on the frequency of these
interactions [31, 32]; and two focused on the reasons be-
hind such interactions [33, 34]. The detailed themes and
extracted text is presented in Additional file 3. Study
and participants’ characteristics can be found in Table 1.
Theme 1.0: The Frequency of PRs visits
The first step in investigating and understanding the
interaction between the PRs and the prescribers is to de-
termine how frequent such interactions are, and if they
are significant enough.
Research has shown that frequency of PR visits to
physicians- skilled health-care professionals trained and
licensed to practice medicine- is considered to be a good
indicator of an active relationship between physicians
and the pharmaceutical industry. Lieb et al. reported
that 77.0% (n = 160) of German respondents met with
PRs at least once a week, and 19.0% (n = 39) were visited
by PRs on a daily basis [29]. Other studies also reported
that PRs visit physicians regularly in order to promote
their products [9, 21, 22, 26, 29, 32]. De Ferrari et al.
studied the relationship between the specialty of the pre-
scriber and the frequency of PR visits [9]. Physicians in-
volved in teaching and those practicing paediatric
medicine, were reported to receive more frequent visits,
while anaesthetists were found to be least frequently
visited by PRs [9]. Two studies reported that PRs vis-
ited physicians working in a private setting more fre-
quently, while physicians working in community and
university hospitals experienced less frequent visits
[22, 23].
Theme 2.0: Perceived ethical acceptability of the PR-
physician interactions
The job of PRs is to introduce and market their com-
pany’s products. PRs ensure that physicians are informed
of the benefits of the products and are therefore willing
to prescribe them to their patients. The interaction be-
tween PRs and physicians entails a number of marketing
methods such as gifts, sponsorships, free drug samples
and free lunches. Moreover, in recent years, simple
brand reminders such as stationery with the company’s
logo and product name on them have increasingly been
replaced by gifts of greater value, ranging from jewellery
to iPads [30]. According to policymakers, such gifts have
the potential to act as an ethical inducement and
negatively impact prescribing behaviour and, ultimately,
patient health [11, 30]. Brett et al., for example, con-
ducted a survey in South Carolina where physicians were
asked to rate 18 scenarios of interactions between physi-
cians and PRs from the most ethically appropriate
(score = 0) to the least ethically appropriate (score = 5).
Results showed that physicians made distinctions about
the ethical appropriateness of gifts of different value and
different type; recreational gifts were rated to be signifi-
cantly less ethically appropriate than educational gifts, as
were the more expensive gifts [23]. According to De Fer-
rari et al., activities perceived to be most ethical were the
provision of medical samples (81.8%) and continuing
medical education (68.9%) [9, 25]. Roy et al. further
added that, in India, some physicians justify gifts as
compensation for the time spent listening to the PR,
time which could have been spent on a patient [30].
“PRs never try to bribe to sell their drug. (Gifts)
are just a gesture to say thanks for the time the
doctor gives. Let’s say a doctor sees three patients
in 15 minutes, the PR us costing him those three
patients in his 15-minute talk. So the PR tries to
compensate with gifts since obviously he can’t
compensate in cash” [30].
In contrast, there were others who felt that air condi-
tioners, washing machines, microwaves, cameras, televi-
sions and expensive crystals were acceptable gifts [30].
Theme 3.0: Physicians’ attitudes towards PR visits
The physician’s attitude is what determines whether they
would be inclined to believe the information provided by
the PR. Qualitative data demonstrating the attitude of
physicians are presented in Additional file 4: Table S3.
3.1 Perceived legitimacy of the PR
Legitimacy refers to the accuracy and accountability of
the PRs as a source of information. According to Prosser
et al., a relationship has been observed between the fre-
quency of visits and the perceived legitimacy of the in-
formation provided: the more frequently visited
physicians were more likely to consider the information
provided to be of “high quality” [33].
Physicians have been reported, in a number of
studies, to consider the information provided by the
PRs as “not trustworthy”, “very variable” and “depend-
ing on which PR you see”; they also disclosed that the
PRs usually choose the promotion of their company’s
product over the actual benefits for the patient by
hardly ever mentioning the drug interactions and the
side-effects [9, 21, 29, 30, 33].
On the other hand, some physicians from a number of
different studies recognized the professional authority of
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Table 1 Characteristics of the included studies
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PRs as information providers and expressed satisfaction
with the information provided. Just under half of all the
participants (47.6%) in a study in Peru, for example,
stated that the information provided by PRs helps them
“learn about new products” and “stay up-to-date”. Simi-
larly, Roy et al. reports that physicians were satisfied
with the information provided despite the fact that side-
effects were hardly ever mentioned [30]. De Ferrari et al.
also reported that 24% of faculty (n = 10) and 18% of
psychiatry residents (n = 3) believed that PRs provide
useful and accurate information on new drugs [9].
Overall, while opinions on this matter differ among
physicians, it can be concluded that physicians consider
the information provided by PRs, factual but, to an ex-
tent, biased.
3.2 Perceived benefits of the interaction with PRs
The perceived benefits of the interaction are the rea-
son why physicians continue to see PRs, despite
knowing that the information provided by them may,
in some cases, be biased. These perceived benefits are
explained below.
3.2.1 Easy access to information Research indicates
that physicians considered the convenience of acquiring
information from PRs, regarding both old and new
drugs, to be the main benefit of meeting with them, This
is true regardless of the country the physicians practiced
in [21, 23, 24, 26, 29, 33, 34].
Physicians also reported that PRs are useful for obtain-
ing research papers and journal off-prints. Physicians’
busy schedules leave them no time to look for evidence.
Thus, representatives are seen as ‘short-cuts’ and “valu-
able sources of information”, simplifying the acquisition
and evaluation of new product information [33].
“I’m sure you could manage if you didn’t see another
drug rep and I’m sure you could get the information if
you wanted to, it’s just that it’s not that accessible, and
it’s also whether you would have the time to actually
sit and read it” [33].
“Although you try and keep up with journals and such
like that, some things go by, you do miss things. So I
feel like I’m keeping up to date a little bit. If I didn’t
see reps I feel that I would be slightly disadvantaged
in terms of my awareness of medications coming
through” [33].
“[It is positive] that they can inform us about new
products […] being launched in the market for the first
time. Secondly, we can [hear about] alternatives from
other companies that have the same effectiveness, low
cost and less side effects” [21].
The user-friendly and face-to-face nature of the inter-
actions permits physicians to ask questions, and get in-
stant answers;
“ I think the answer is it’s user friendly, it’s very user
friendly and its easy listening, you know, with your
coffee listening to what they’ve got to say” [33].
Furthermore, according to Prosser et al. [33], several
physicians have commented that they remember the in-
formation better when communicated verbally;
“ I can remember the information better after having
talked to them” [33].
“Seeing a representative face to face tends to make a
more lasting impression than reading” [33].
3.2.2 Free gifts and drug samples The other perceived
benefit of meeting PRs is the gifts and free samples pro-
vided by them. Such gifts can range from materials that
are supposed to directly help the patients (blood sugar
diaries, educational materials) to personalized gifts for
the doctor; from cheap stationery to expensive so-called
gifts that act as inducements [21, 34]. According to
Table 1 Characteristics of the included studies (Continued)
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Alssageer et al.(n = 423) 86% of respondents reported to
have received printed material (n = 480; 79%), simple
gifts (stationery, n = 442; 73%) or drug samples (n = 418;
69%) at least once during the last twelve months [31].
“Sometimes we need representatives in providing some
medicines that we need it, some books or bulletin.
Really, they help us in getting books, CDs and lectures
from abroad that provided by some companies. They
support us on this side a lot” [21].
Free medication samples are the most frequently ac-
cepted gifts in the US and Germany. Physicians consider
these gifts to be the most ethically acceptable and a great
advantage of meeting with PRs [9, 29, 34].
Physicians and PRs justify such gifts on the grounds
that free medications can be used to help patients who
are unable to afford medications due to financial
constraints. Free samples can also be used to determine
the dose and side-effects before the patient has to invest
in them [34, 36].
“We want to make people happy and you make people
happy often when you give them a sample” [34].
Morgan et al. reported that the main reason for which
the free drug samples are distributed is patients’ financial
needs, followed by patients’ convenience and to build
a good relationship with the patient, but less than
two-thirds of physicians distributed free samples with
a good basis of knowledge as to the efficacy of the
sample product [25].
3.2.3 Social aspects of the interaction Some physicians
liked the casual, friendly aspect of the interaction and
thought of the representatives as more of their friend
than a promoter;
“Going out to dinner as a group….That’s why we do it,
more of a social setting outside of the wards” [34].
3.3 Perceived drawbacks of the interaction with PRs
Despite the above-mentioned positive attitudes towards
PRs, the prescribers do admit that there are certain
drawbacks to seeing PRs. These drawbacks, in their
opinion, are:
3.3.1 Negative impact on the patient Some physicians
believe that PRs take up a proportion of the doctor’s time,
which could have been spent attending to patients [29, 30].
“Doctors always perceive MRs’ visits as an intrusion.
Every minute taken up by the MR is time which could
have been spent seeing patients and making money in
the clinic. Often, MRs queue up early in the morning
for doctors who allow only the first three MRs to see
them” [30].
Al-Areefi et al. reported that some physicians hate the
fact that PRs interrupt their patient care process, espe-
cially those working in the emergency departments with
a high workload and a large number of patients to at-
tend to. These physicians have absolutely no time to lis-
ten to PRs and even refer to them as “time wasters” [21].
Some other physicians reported discomfort with or dis-
like of the interactions, and this appeared to be rooted in
their perception that PRs harm the ethical reputation of
the profession and adversely affect patients [21, 34].
“My rule is I [listen but] don’t believe anything they’re
saying” [34].
3.3.2 Pressure from PRs Studies suggest that drugs
often complain about the “pushy” behaviour of PRs that
puts them under pressure to prescribe a certain product
from a certain company. They have been reported to
have experienced aggressive sale techniques, which they
defined as: asking physicians to justify their current pre-
scribing and even direct requests using emotional ap-
peals to the physicians to prescribe a certain medicine as
a favour to the PR. Such aggressive marketing methods
are criticized by physicians [29, 30, 33].
“Such approaches could discourage prescribing a
representative’s product or seeing a particular
representative again. What we don’t like is a drug rep
coming in and questioning us, because I don’t think
that’s their role or asking us what we do prescribe, and
then why. We don’t like that. Some of them can be
quite pushy” [33].
“In some cases, the representative imposes on the
physician to prescribe a certain product. We can
prescribe it in rare cases for some diseases. Some
representatives say: I have certain amount of medicine
in your pharmacy and it's not dispensing, prescribe,
just one or two’. This forced us to refuse to meet him
again, because he imposes [on] me to prescribe his
product for any patient without any reason” [21].
Studies also indicate that physicians feel obliged to the
PR because of previous service they may have provided.
Although this is not a direct pressure from the PR, it
can still pressure the prescribers indirectly and affect
their prescription patterns, which they dislike [21].
Both direct and indirect pressure from PRs are disliked
by physicians and can result in the physician deciding to
stop seeing that particular PR [29, 30, 33].
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Theme 4.0: Physicians’ perceptions of the effect of PR
visits on prescription patterns
Physicians’ perception as to whether or not their pre-
scribing is influenced by PRs is very important since it
can determine their attitudes towards PRs [37].
Wang et al. reported that 36% (n = 32) of ophthal-
mology trainees reported having changed prescribing
behaviour based on the information provided by a
PRs, 77% (n = 94) stated that they changed prescribing
behaviour based on the availability of medicine sam-
ples [27].
Research shows, however, that the majority of physi-
cians are convinced that PR visits do not influence their
prescribing behaviour [24, 26, 27, 29, 31, 32, 34, 36]. De
Ferrari et al. reported that about 88% of study respon-
dents disclosed that they believe receiving gifts or going
for company sponsored lunches does not affect their
prescribing [9]. All 15 included studies illustrated one
common point: that physicians almost always believe
that such interactions can influence their colleagues’
prescription patterns but not theirs; Roy et al. has for
example, revealed that most physicians usually do not
admit having accepted gifts from PRs and even if they
do, they usually believe it does not affect their prescrib-
ing. Almost all of them, however, claim to know col-
leagues who accept gifts and whose prescribing
behaviour is influenced by this [30, 38].
“I think drug reps are a good thing…Just because I
have a pen with the name of a drug on it, doesn’t
mean I’m going to prescribe it” [33].
The other reason stated by the physicians for their
perceived immunity against biased information is the
friendship between them and the PR over the years:
“I think if you see a rep who you know well … it’s the
same rep who you’ve seen for several years, they don’t
try and pull the wool over your eyes. They know that if
they tell you lies you’ll be seeing them again in six
months and you’ll find them out” [33].
On the contrary, some other physicians found this
very same social bond to be the main reason their pre-
scribing behaviour being affected; they felt they were
sometimes influenced to prescribe a particular medicine
due to their long term and continuous relationship with
the representative [33].
Theme 5.0: Reasons to accept/reject PRs
Understanding the reasons behind physicians accept-
ing PRs would be a breakthrough in understanding
the overall nature of the interaction between PRs and
prescribers [35].
5.1 Reasons for accepting PRs
5.1.1 Sponsorship, gifts One incentive behind meet-
ing PRs is the sponsorship, gifts and products pro-
vided by them.
“We were building a new surgery and, you know, we
needed some sponsorship” [33].
“I don’t mind a nice hotel for a weekend. You don’t get
many perks unfortunately as a GP, and I don’t see a
problem in that” [33].
“I work in non-profit…you know [reps] do provide
me with pens…[and] somehow my administrator
doesn’t want to spend too much money on office
supplies” [34].
5.1.2 Social aspect of the interaction Friendship and
the social bonds made between physicians and PRs over
the years has been proven to have a direct effect on the
physicians’ decisions on whether or not to accept a PR.
Some physicians considered these meetings as a chance
for social interaction and as a break from their busy
work routine [21, 33].
The social aspect of the interaction is even strong
enough that the physicians who have stopped seeing
PRs still make exceptions for the ones who are their
friends:
“Some reps I’ve known for donkey’s years and they
know all about my life and I know all about their life
and you have a chat about things which are totally
unrelated to why they came, but it does make life
more interesting and you’re probably more likely to
actually retain what they came in to tell you if you’ve
had a pleasant time talking to them about your kids
or something” [33].
Participants reported that they sometimes accepted
the PRs not because they want to hear about new drugs
but just to enjoy the social aspect of the visits.
“Sometimes we don’t even talk about drugs, we just
chat about the kids and it’s good to have a relaxed
and friendly lunch” [34].
5.1.3 Courtesy and tradition Another reason for phy-
sicians to agree to meet PRs is the matter of cour-
tesy, where physicians accept to meet a PR just so
that they are not rude; some of the sample com-
ments are as follows:
“I think they have a very difficult job. There will be
an element of empathy for somebody who comes and
says can I talk to you about something. Out of
politeness, really” [33].
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“I know it’s just the guy’s job, and if I don’t talk to him
then he may lose it, so I talk to him” [33].
“The other side is to facilitate services for
colleagues as they do this task [to support] their
families. This refers to a social and economic
situation for colleagues because he gets a payoff
to spend on his family” [21].
Some physicians accepted representatives simply be-
cause it was tradition or, in other words, part of the job
of a physician. Some reported ‘inheriting’ such visits
from their previous colleagues, the practice then becom-
ing part of their routine [23].
5.2 Reasons for avoiding/rejecting PRs
Not all physicians readily accept PRs, there are a few
physicians who either have a certain criteria for choosing
PRs or choose to avoid them completely [23]. The cri-
teria used by some physicians are: personal style, com-
pany and the kind of drugs PRs offer.
“I have specific criteria for selection. I mean,
whether I like this representative or not, whether I
am comfortable with him or not and whether his
style is true or not true. Is he logical or not logical?
There are companies that [I] do not care about
them. For example, a new company whose products
are widely available such as popular products. I
often do not meet them because they do not give
us new ideas” [21].
One of the physicians who avoids PRs’ comments:
“Really, from the time that I came here to work, I
[have tried] to avoid meeting them because my use is
limited, but I have to meet my colleagues. I try to
avoid the interview because I know that I will not
prescribe his product. I am a surgeon and my use is
limited. Just I have painkiller. There is no other
choice” [21].
Physicians cited many reasons for refusing to meet
PRs, such as bad experience with PRs and commercial
context (e.g., disagreements about some commercial
deal), obligations to other companies, lack of conviction
about the product, lack of credibility of PRs and work-
load or inappropriate timing of visits [21, 33].
“The other thing, I may refuse to meet [a]
representative if the owner of the company behaves
with our colleagues [in an] inhuman or dishonorable
[way], so this forces us to stop prescribing its product
and prescribe a similar alternative that exists in the
market” [21].
Reasons for avoiding PRs, other than the ones men-
tioned above, were: commercially-biased information,
pushy and argumentative approach, and a lack of accur-
acy in the information provided, and, finally, the PR’s in-
fluence on prescribing behaviour.
“I have been very influenced in the past by my
prescribing so I don’t see them anymore now. I was
getting no advantage from it at all, it was skewing my
prescribing and I was losing a lot of time, so I stopped
seeing them” [33].
Theme 6.0: Guidelines
6.1 Guidelines and their impact
Over the years, there have been a number of guidelines
developed by different healthcare societies regarding the
interaction between physicians and PRs such as; the
American College of Obstetricians and Gynecologists
(ACOG), the American Medical Association (AMA) and
the Association of American Medical Colleges, Canadian
Medical Association (CMA). Morgan et al. [25] and
Anderson et al. [28] have each investigated the use and
effect of guidelines in the US. Anderson et al. reports
that 154 (62%) of participants in the US were familiar
with guidelines on interacting with the pharmaceutical
industry, of whom 81 (33%) had read guidelines devel-
oped by ACOG, 86 (35%) had read AMA guidelines, and
49 (21%) had read guidelines from other sources such as
hospital guidelines, journal articles, and continuing med-
ical education programmes [28].
Studies show that those who had read the guidelines
would actually provide fewer free samples to patients or
have less frequent meals with the PRs. They were also
less likely to receive first hand news on medical products
from PRs or include PRs in the decision as to whether
to prescribe a new drug, compared to those who had not
read the guidelines [25, 28].
According to Anderson et al., there was no significant
difference between those who reported reading ethical
guidelines and those who did not do so pertaining to
using PRs for obtaining drug information [28]. It is pos-
tulated that having read guidelines did not affect the per-
ceived value of PRs [28].
6.2 Physician’s opinion on guidelines that restrict physician-
PR interactions
The opinion of physicians on the policies that limit or
prohibit the physician-PR interaction varied significantly.
Some participants believed such restrictions to be unfair
to prescribers and patients; some welcomed them with
open arms. While others reported having doubts about
policies, particularly those related to prohibition of free
drug samples. These physicians however, disclosed that,
over time they realized that their prescribing behaviour
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had actually been affected by the visits of PRs and avail-
ability of free drug samples, and they eventually started
supporting policies that prohibit/restrict PR visits. In a
study done in the US in 2003, 39.9% of participants
stated that they disagreed with placing limitations on the
interaction between physicians and PRs, while roughly
the same percentage (33.3%) agreed with the policy. In
Germany the data is slightly different, over half of the
German physicians (n = 108; 52%) indicated that they
would regret the cessation of the visits while the
remaining 45% (n = 94) supported it [29, 34].
“I was really hesitant about getting rid of the sample
closet years ago, but now I think it was really,
definitely the right thing because I would reach for the
best non-steroidal that was in there and at that point
it was [brand name]. So I give a patient [brand name]
thinking I did a good thing because he told me he
didn’t have any money, but often they would come
back wanting [brand name] where I just could have
given him Ibuprofen. …Once we didn’t have it any-
more, I realized that…” [34].
Discussion
As part of the health care system, pharmaceutical manu-
facturers have benefited countless people through their
investment in research and product development. Their
ultimate responsibility, however, is to their shareholders,
who expect a reasonable profit from their investments
[6]. The pharmaceutical industry, therefore, cannot be
entirely blamed for trying to increase returns, within
legal boundaries. Inappropriate marketing practices that
may arise from this profit-led competition have been
proven, however, to have the potential to influence phys-
ician prescribing.
Policymakers have therefore tried to restrict the inter-
action between physicians and PRs, which is where most
of the marketing occurs, by developing guidelines and
making relevant policies. The World Health Assembly,
in an attempt to tackle the issue, adopted the WHO Eth-
ical Criteria for Medicinal Drug Promotion in 1988,
which requires PRs to have an appropriate educational
background and be adequately trained with sufficient
medical and technical knowledge and integrity to present
information on products in an accurate, unbiased, and re-
sponsible manner. WHO also holds employers respon-
sible, for not only the basic and continuing training of
their representatives, but also for their statements and ac-
tivities [39]. Many critics, however, have complained that
these guidelines have been largely disregarded, including
the voluntary Code of Pharmaceutical Practices developed
by the industry’s own International Federation of Pharma-
ceutical Manufacturers’ Associations (IFPMA) [1]. While
the development of guidelines and policies has proven
helpful, therefore, it certainly is not enough..
As demonstrated by this meta-synthesis, the attitude
of physicians towards PRs is a very crucial determinant
of the potential of PRs to indirectly influence the health
of patients in a positive or negative way. The studies in-
cluded in this meta-synthesis were undertaken in nine
different countries with significantly different economies,
cultures, education/healthcare systems, and health pol-
icies, yet the positive attitude of physicians towards PRs
was evident in all of them.
As stated earlier, there are a number of reasons behind
this positive attitude with the one-to-one medium of
interaction being one of them; the results of the research
conducted by McGettigan et al. showed that the infor-
mation sources most frequently rated important by phy-
sicians were not those most used in practice. The
sources of practical importance were those involving the
transfer of information through personal face-to-face
contact, indicating the importance of the medium
through which information is conveyed [40] which poses
an advantage for direct pharmaceutical detailing.
Lack of time to read and keep abreast of the myriad of
new medical information is another important facilitator
for physicians to meet PRs. PRs are seen as convenient
and timely sources of medicine related information. Phy-
sicians perceive the information provided by PRs as fac-
tual but in some cases biased. Our findings are in line
with that of the systematic review conducted by Wazana
et al. [11];physicians believe that they are immune from
any potential marketing influence. This is mainly be-
cause most of physicians believe that they have the
required expertise and knowledge to assess the pre-
sented information and distinguish the valid informa-
tion from the exaggerated, biased information [21, 22,
24–27, 29, 32–34]. This is despite the clear evidence
in the literature regarding the effect of PRs on pre-
scribing behaviour [32].
Undeniably, detailing poses as a convenient face-to-
face educational meeting [21, 23, 24, 26, 29, 33, 34],espe-
cially for newly launched medicines [33, 35]. Instead of
seeking to ban these interactions, therefore, medical
regulatory bodies could implement proactive measures
to educate medical students about potential medical in-
ducements [10]. Vinson et al. measured the effect of a
one-hour lecture and discussion about the appropriate-
ness of pharmaceutical gifts among second-year medical
students. Findings from the survey have showed that
these students had become statistically significantly
more resistant to the gifts compared to the first-year stu-
dents who served as a control group and had not experi-
enced the lecture. This study strongly suggested that
changes in students’ attitudes towards marketing
methods used by PRs may be fostered [41]. Similarly,
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positive long term effects were observed from educating
trainees and physicians about understanding and respond-
ing to pharmaceutical promotion [42–44].
We believe that this meta-synthesis has given new in-
sights into the PR-physician interaction. The findings of this
meta-synthesis have implications for policy makers and ed-
ucators. Future research should focus on practical educa-
tion and policy interventions to better limit any potential
conflict of interest that may arise from such interactions
through education and informed policy development.
Limitations
This meta-synthesis focused on the recent literature and
excluded studies published before 2000. This means that
some relevant, important points might have been missed
if they were published before 2000. Meanwhile, the
themes were generated in such a way as to offer, in the
authors’ opinion, a useful insight into the different as-
pects of the PR-physician interaction. Drawing together
data from multiple countries has some value, certainly.
However, looked at from the opposite point of view, it is
not entirely clear that the cultures of pharmaceutical
companies and of physicians, and the regulatory/health-
care systems in countries as diverse as Peru, India, the
Yemen, the UK and the US can be easily comparable.
Direct to consumer advertising is, for example allowed
in US but banned in other countries. Thus, there is a
need for some further country specific studies.
Conclusions
The purpose of this meta-synthesis, was to highlight the de-
tailing aspects of PR-physician interactions from the physi-
cian’s point of view. This meta-synthesis shows that
physicians generally see meetings with PRs as advantageous
to everyone: the patients, because they receive free drug
samples, the hospital/clinic, because they would receive
stationery, books, and, most importantly, themselves, as
these meetings help them to stay up-to-date and aware of
newly launched medications. Future research should focus
on educating medical students to correct their perception
of immunity against marketing which may hold them back
from critically appraising the information provided by PRs.
This will ensure that patients do not bear the cost of com-
petition between pharmaceutical companies.
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